Dupixent 300 mg/2mL
Dupilumab · INJECTION, SOLUTION · Sanofi-Aventis U.S. LLC
No Recall History
Plain English
Dupixent is a injection, solution containing dupilumab at 300 mg/2mL, taken subcutaneous. Manufactured by Sanofi-Aventis U.S. LLC.
Key Facts
- Brand Name
- Dupixent
- Generic Name
- Dupilumab
- NDC Code (Product)
0024-5914- Manufacturer
- Sanofi-Aventis U.S. LLC
- Strength
- 300 mg/2mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761055
- Drug Class
- Interleukin-4 Receptor alpha Antagonist [EPC]
- Marketing Start
- 03/28/2017
Recall History
No Recall HistoryFrequently Asked Questions
What is Dupixent used for?
Dupixent contains Dupilumab. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is Dupixent a controlled substance?
Dupixent is not classified as a controlled substance by the DEA.
What is the generic name for Dupixent?
The generic name for Dupixent is Dupilumab. There are no other listed brand versions of Dupilumab.
What is the NDC code for Dupixent 300 mg/2mL?
The NDC (National Drug Code) for Dupixent 300 mg/2mL is 0024-5914, listed by Sanofi-Aventis U.S. LLC.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)